Vis enkel innførsel

dc.contributor.authorBaldia, Philipp Heinrich
dc.contributor.authorWernly, Bernhard
dc.contributor.authorFlaatten, Hans Kristian
dc.contributor.authorFjølner, Jesper
dc.contributor.authorArtigas, Antonio
dc.contributor.authorPinto, Bernardo Bollen
dc.contributor.authorSchefold, Joerg C.
dc.contributor.authorKelm, Malte
dc.contributor.authorBeil, Michael
dc.contributor.authorBruno, Raphael Romano
dc.contributor.authorBinnebößel, Stephan
dc.contributor.authorWolff, Georg
dc.contributor.authorErkens, Ralf
dc.contributor.authorSigal, Sviri
dc.contributor.authorvan Heerden, Peter Vernon
dc.contributor.authorSzczeklik, Wojciech
dc.contributor.authorElhadi, Muhammed
dc.contributor.authorJoannidis, Michael
dc.contributor.authorOeyen, Sandra
dc.contributor.authorMarsh, Brian
dc.contributor.authorAndersen, Finn Husøy
dc.contributor.authorMoreno, Rui
dc.contributor.authorLeaver, Susannah
dc.contributor.authorDe Lange, Dylan W.
dc.contributor.authorGuidet, Bertrand
dc.contributor.authorJung, Christian
dc.description.abstractBackground In the early COVID-19 pandemic concerns about the correct choice of analgesics in patients with COVID-19 were raised. Little data was available on potential usefulness or harmfulness of prescription free analgesics, such as paracetamol. This international multicentre study addresses that lack of evidence regarding the usefulness or potential harm of paracetamol intake prior to ICU admission in a setting of COVID-19 disease within a large, prospectively enrolled cohort of critically ill and frail intensive care unit (ICU) patients. Methods This prospective international observation study (The COVIP study) recruited ICU patients ≥ 70 years admitted with COVID-19. Data on Sequential Organ Failure Assessment (SOFA) score, prior paracetamol intake within 10 days before admission, ICU therapy, limitations of care and survival during the ICU stay, at 30 days, and 3 months. Paracetamol intake was analysed for associations with ICU-, 30-day- and 3-month-mortality using Kaplan Meier analysis. Furthermore, sensitivity analyses were used to stratify 30-day-mortality in subgroups for patient-specific characteristics using logistic regression. Results 44% of the 2,646 patients with data recorded regarding paracetamol intake within 10 days prior to ICU admission took paracetamol. There was no difference in age between patients with and without paracetamol intake. Patients taking paracetamol suffered from more co-morbidities, namely diabetes mellitus (43% versus 34%, p < 0.001), arterial hypertension (70% versus 65%, p = 0.006) and had a higher score on Clinical Frailty Scale (CFS; IQR 2–5 versus IQR 2–4, p < 0.001). Patients under prior paracetamol treatment were less often subjected to intubation and vasopressor use, compared to patients without paracetamol intake (65 versus 71%, p < 0.001; 63 versus 69%, p = 0.007). Paracetamol intake was not associated with ICU-, 30-day- and 3-month-mortality, remaining true after multivariate adjusted analysis. Conclusion Paracetamol intake prior to ICU admission was not associated with short-term and 3-month mortality in old, critically ill intensive care patients suffering from COVID-19.en_US
dc.rightsNavngivelse 4.0 Internasjonal*
dc.titleThe association of prior paracetamol intake with outcome of very old intensive care patients with COVID-19: results from an international prospective multicentre trialen_US
dc.typeJournal articleen_US
dc.typePeer revieweden_US
dc.rights.holderCopyright 2022 The Author(s)en_US
dc.source.journalBMC Geriatricsen_US
dc.identifier.citationBMC Geriatrics. 2022, 22, 1000.en_US

Tilhørende fil(er)


Denne innførselen finnes i følgende samling(er)

Vis enkel innførsel

Navngivelse 4.0 Internasjonal
Med mindre annet er angitt, så er denne innførselen lisensiert som Navngivelse 4.0 Internasjonal